Check Cap Ltd Company Profile (NASDAQ:CHEK)

Analyst Ratings

Consensus Ratings for Check Cap Ltd (NASDAQ:CHEK) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.50 (535.59% upside)

Analysts' Ratings History for Check Cap Ltd (NASDAQ:CHEK)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Chardan CapitalLower Price TargetBuy$6.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Check Cap Ltd (NASDAQ:CHEK)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Check Cap Ltd (NASDAQ:CHEK)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Check Cap Ltd (NASDAQ:CHEK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Check Cap Ltd (NASDAQ:CHEK)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Check Cap Ltd (NASDAQ:CHEK)
DateHeadline
07/02/16 03:15 PMSoutheastern Grocers debuts sugar-sweetened throwback
07/02/16 03:15 PMSoCal fire officials: Leave the fireworks to the professionals on July 4th
07/02/16 03:15 PMWinn-Dixie Gets Real Retro with Soda
07/02/16 03:15 PMN.J. man wanted in shooting, carjacking eludes police in car chase
03/10/16 06:00 AMCheck-Cap to Present at the 28th Annual ROTH Conference on March 16, 2016 - [PR Newswire] - ISFIYA, Israel, March 10, 2016 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Bill Densel, Chief Executive Officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016 at 9:30am PT, 12:30pm ET. The conference will be held on March 13-16, 2016 at the Ritz Carlton in Dana Point, California. Unlike other imaging examinations, Check-Cap's technology does not require prior bowel preparation, fasting, or other disruptions to normal daily routines. Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, and the second leading cause of cancer-related deaths when both genders are combined. The American Cancer Society recommends regular screening starting at age 50 for all men and women at average risk for developing colorectal cancer. However, more than one-third of Americans in this group are not up-to-date with testing recommendations that can prevent colorectal cancer.
01/23/16 12:21 PMCheck-Cap Ltd. (CHEK) - Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for precancerous polyps and colorectal cancer. Its lead product is an endoscopy ...
12/14/15 06:00 AMCheck-Cap Announces the Publication of Preliminary Clinical Data on its Preparation-Free Colon Screening Capsule in Gut - [PR Newswire] - ISFIYA, Israel, Dec. 14, 2015 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that data related to its clinical studies have been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology. The article, entitled "A Novel Prepless X-ray Imaging Capsule for Colon Cancer Screening," includes safety and motility data collected in Europe and Israel on passage of the capsule through the GI tract, as well as a preliminary analysis of the first participants evaluated in the Company's ongoing multi-center clinical feasibility study, which aims to establish the safety, functionality and preliminary efficacy of the Check-Cap system.
12/08/15 12:12 PMCHECK-CAP LTD Financials -
11/25/15 06:00 AMCheck-Cap CEO to Present at LD Micro Main Event on December 2, 2015 - [PR Newswire] - ISFIYA, Israel, Nov. 25, 2015 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development ...
10/26/15 06:00 AMCheck-Cap Featured at the World Endoscopy Organization Colorectal Cancer Screening Committee Meeting - [PR Newswire] - ISFIYA, Israel, Oct. 26, 2015 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development ...
10/22/15 06:00 AMCheck-Cap Reports Third Quarter 2015 Financial Results - [PR Newswire] - ISFIYA, Israel, Oct. 22, 2015 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development ...
10/20/15 05:10 AMCheck-Cap Announces New Data Demonstrating Safety and Detection of Polyps in Clinical Study Evaluating Preparation-Free Colorectal Cancer Screening Capsule - [PR Newswire] - ISFIYA, Israel, Oct. 20, 2015 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced new data demonstrating safety and polyp detection from a clinical study evaluating the company's non-invasive system for preparation-free examination of the colon. Results will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 16-21, 2015 and the United European Gastroenterology Week (UEGW) taking place October 24-28, 2015. "Despite a compelling body of clinical evidence demonstrating that routine colonoscopies are effective in the early detection of colorectal cancer, studies suggest that only approximately 65 percent of patients in the target population adhere to current screening guidelines.
08/26/15 06:00 AMCheck-Cap to Present at the Rodman & Renshaw 17th Annual Global Investment Conference - [PR Newswire] - ISFIYA, Israel, Aug. 26, 2015 /PRNewswire/ -- Check-Cap Ltd. ("Check-Cap" or the "Company")(Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, announced today that Bill Densel, Check-Cap's Chief Executive Officer, will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, September 9, 2015 in New York City. Mr. Densel, who was recently appointed as the Chief Executive Officer of Check-Cap, will provide a company overview and discuss the status of Check-Cap's ongoing clinical program. The Company is developing an ingestible capsule that utilizes proprietary, ultra-low-energy X-ray-based technology to safely generate high-resolution, 3-dimensional imagery of the interior of the colon.
08/13/15 08:30 AMCheck-Cap Announces Appointment of William Densel as Chief Executive Officer and Director - [PR Newswire] - ISFIYA, Israel, Aug. 13, 2015 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, announced today the appointment of William (Bill) Densel as Chief Executive Officer. The terms of Mr. Densel's engagement as Chief Executive Officer were approved at an extraordinary general meeting of shareholders held today. In addition, Check-Cap's Board of Directors elected Mr. Densel as a director to fill a vacancy on the Board, to serve in such office until the next annual general meeting of shareholders, effective as of the approval of the terms of his engagement as Chief Executive Officer by the Company's shareholders. Mr. Densel joined Check-Cap earlier this year as President of U.S. Operations.
07/21/15 07:00 AMCheck-Cap Reports Second Quarter 2015 Financial Results - [PR Newswire] - ISFIYA, Israel, July 21, 2015 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development ...
07/06/15 06:00 AMCheck-Cap Announces Extraordinary General Meeting of Shareholders to be held on August 13, 2015 - [PR Newswire] - To approve the terms of engagement of Mr. William Densel, as Chief Executive Officer. "Capitalizing on the progress made by Check-Cap and the success of our initial public offering in the United States earlier this year, the Board has determined that it is in our best interest to engage Mr. William (Bill) Densel as our Chief Executive Officer to lead the company through its next phase of growth.
06/24/15 03:01 PMCheck-Cap Extends Registration Deadline for Holders of Ordinary Shares Purchased in its Initial Public Offering to be Eligible to Receive Long Term Incentive Warrants to August 23, 2015 - [PR Newswire] - Holders of ordinary shares underlying units purchased in Check-Cap's initial public offering who currently hold such ordinary shares in "street name" are advised to contact their brokers to initiate the process of registering these ordinary shares in their own names as soon as possible. Brokers should check within their firm's operations department for guidance on registering ordinary shares for their clients out of "street name." Any holder who fails to register the ordinary shares underlying the units purchased by such holder in Check-Cap's initial public offering by August 23, 2015, will not be eligible to receive any Long Term Incentive Warrants.
06/04/15 08:15 AMCheck-Cap Reports First Quarter 2015 Financial Results and Provides Corporate Update - [PR Newswire] - ISFIYA, Israel, June 4, 2015 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development ...
05/19/15 09:37 AMCheck-Cap Expands Management Team with Appointment of Bill Densel as President of U.S. Operations - [PR Newswire] - Mr. Densel will lead Check-Cap's U.S. operations out of Boston, Massachusetts. In this role, he will be responsible for overseeing Check-Cap's clinical program in the United States, including the Company's planned U.S. pivotal trial. Additionally, Mr. Densel will be involved in planning the Company's regulatory program for the United States and Canada and will lead the development of the global sales and marketing strategy in the United States, Canada and Latin America.
05/15/15 04:00 PMCheck-Cap Issues Reminder to Shareholders Who Purchased Units in its Initial Public Offering Regarding Long Term Incentive Warrants - [PR Newswire] - ISFIYA, Israel, May 15, 2015 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule screening for colorectal cancer, reminds the holders of its ordinary shares who purchased units in its initial public offering that in order to be eligible to receive and exercise the Long Term Incentive Warrants that are to be issued to the purchasers of such units, they must register the ordinary shares underlying the units purchased by them in Check-Cap's initial public offering in their own names and not in "street name" by no later than June 24, 2015. Any holder who fails to register the ordinary shares underlying the units purchased by such holder in Check-Cap's initial public offering by June 24, 2015 will not receive any Long Term Incentive Warrants. Holders of Long Term Incentive Warrants who currently hold ordinary shares underlying units purchased in Check-Cap's initial public offering in "street name" are urged to contact their brokers to initiate the process of registering these ordinary shares in their own names as soon as possible.
05/12/15 08:23 AMCheck-Cap to Present at the 2015 Marcum MicroCap Conference on May 28, 2015 - [PR Newswire] - ISFIYA, Israel, May 12, 2015 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule screening for colorectal cancer, today announced that Guy Neev, Chief Executive Officer, will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City. Check-Cap's imaging capsule is designed for the detection of colorectal cancer and clinically-significant pre-cancerous polyps. Unlike other colon screening methods, Check-Cap's imaging capsule can be used without prior fasting or cleansing of the colon. Colorectal cancer is the second leading cause of death from cancer in the United States, but roughly one-half of Americans over the age of 50 do not undergo colon cancer screening due in large part to the pain, discomfort and embarrassment related to current screening methods.

Social

About Check Cap Ltd

Check Cap Ltd logoCheck-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company's system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient's back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company's scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient's body that stores the information for off-line analysis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CHEK
  • CUSIP:
Key Metrics:
  • Previous Close: $1.18
  • 50 Day Moving Average: $1.32
  • 200 Day Moving Average: $2.27
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $15.67M
  • Beta: -0.01
  • Current Year EPS Consensus Estimate: $-0.80 EPS
  • Next Year EPS Consensus Estimate: $-0.74 EPS
Additional Links:
Check Cap Ltd (NASDAQ:CHEK) Chart for Saturday, July, 23, 2016